{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-10-23",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "discontinued_date": "06/15/2026",
      "update_type": "New",
      "initial_posting_date": "06/15/2026",
      "package_ndc": "0069-0227-03",
      "generic_name": "Lorlatinib Tablet",
      "contact_info": "800-533-4535",
      "related_info": "Supply expected to exhaust 6/30/2026; NDC 0069-0227-01 25 mg; 30 tablets bottle with a child-resistant closure will continue to be manufactured; Discontinuation of the manufacture of this presentation",
      "openfda": {
        "application_number": [
          "NDA210868"
        ],
        "brand_name": [
          "LORBRENA"
        ],
        "generic_name": [
          "LORLATINIB"
        ],
        "manufacturer_name": [
          "Pfizer Laboratories Div Pfizer Inc"
        ],
        "product_ndc": [
          "0069-0227",
          "0069-0231"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "ORAL"
        ],
        "substance_name": [
          "LORLATINIB"
        ],
        "rxcui": [
          "2103169",
          "2103175",
          "2103177",
          "2103179"
        ],
        "spl_id": [
          "46cb56ce-da15-49af-b72b-f9e377cae4a6"
        ],
        "spl_set_id": [
          "2b34d62d-e02a-4af3-bc0d-1571dd4ee76d"
        ],
        "package_ndc": [
          "0069-0227-01",
          "0069-0227-03",
          "0069-0231-01"
        ],
        "nui": [
          "N0000175605",
          "N0000175082",
          "N0000190118",
          "N0000191264",
          "N0000187064",
          "N0000191265",
          "N0000190111",
          "N0000191423",
          "N0000190113"
        ],
        "pharm_class_epc": [
          "Kinase Inhibitor [EPC]"
        ],
        "pharm_class_moa": [
          "Kinase Inhibitors [MoA]",
          "Cytochrome P450 3A Inducers [MoA]",
          "P-Glycoprotein Inducers [MoA]",
          "Cytochrome P450 2B6 Inducers [MoA]",
          "Organic Cation Transporter 1 Inhibitors [MoA]",
          "Organic Anion Transporter 3 Inhibitors [MoA]",
          "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]",
          "Breast Cancer Resistance Protein Inhibitors [MoA]"
        ],
        "unii": [
          "OSP71S83EU"
        ]
      },
      "update_date": "06/15/2026",
      "therapeutic_category": [
        "Oncology"
      ],
      "dosage_form": "Tablet",
      "presentation": "Lorbrena, Tablet, 25 mg; 120 tablets bottle with a child-resistant closure (NDC 0069-0227-03)",
      "company_name": "Pfizer Inc.",
      "status": "To Be Discontinued"
    }
  ]
}